These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 27481707)

  • 1. Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets.
    Ramalingam S; Ramamurthy VP; Njar VCO
    J Steroid Biochem Mol Biol; 2017 Feb; 166():16-27. PubMed ID: 27481707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Fararjeh AS; Liu YN
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31181727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Cell Autonomous RON Receptor Expression Promotes Prostate Cancer Growth Under Conditions of Androgen Deprivation.
    Brown NE; Paluch AM; Nashu MA; Komurov K; Waltz SE
    Neoplasia; 2018 Sep; 20(9):917-929. PubMed ID: 30121008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular growth factors as prospective therapeutic targets for combination therapy in androgen independent prostate cancer (AIPC).
    Jonnalagadda B; Arockiasamy S; Krishnamoorthy S
    Life Sci; 2020 Oct; 259():118208. PubMed ID: 32763294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multifocal Signal Modulation Therapy by Celecoxib: A Strategy for Managing Castration-Resistant Prostate Cancer.
    Benelli R; Barboro P; Costa D; Astigiano S; Barbieri O; Capaia M; Poggi A; Ferrari N
    Int J Mol Sci; 2019 Dec; 20(23):. PubMed ID: 31816863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
    Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
    Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond.
    Nakazawa M; Kyprianou N
    J Steroid Biochem Mol Biol; 2017 Feb; 166():84-90. PubMed ID: 27189666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor co-regulatory networks in castration-resistant prostate cancer.
    Sung YY; Cheung E
    Endocr Relat Cancer; 2014 Feb; 21(1):R1-R11. PubMed ID: 24152433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling.
    Zaslavsky AB; Gloeckner-Kalousek A; Adams M; Putluri N; Venghatakrishnan H; Li H; Morgan TM; Feng FY; Tewari M; Sreekumar A; Palapattu GS
    Neoplasia; 2015 Jun; 17(6):490-6. PubMed ID: 26152357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
    Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression.
    Qiao J; Grabowska MM; Forestier-Roman IS; Mirosevich J; Case TC; Chung DH; Cates JM; Matusik RJ; Manning HC; Jin R
    Oncotarget; 2016 Sep; 7(38):61955-61969. PubMed ID: 27542219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.
    Cai Z; Chen W; Zhang J; Li H
    Int Urol Nephrol; 2018 Oct; 50(10):1753-1764. PubMed ID: 30128923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Constitutive Intrinsic Inflammatory Signaling Circuit Composed of miR-196b, Meis2, PPP3CC, and p65 Drives Prostate Cancer Castration Resistance.
    Jeong JH; Park SJ; Dickinson SI; Luo JL
    Mol Cell; 2017 Jan; 65(1):154-167. PubMed ID: 28041912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Checkpoint Kinase 2 Negatively Regulates Androgen Sensitivity and Prostate Cancer Cell Growth.
    Ta HQ; Ivey ML; Frierson HF; Conaway MR; Dziegielewski J; Larner JM; Gioeli D
    Cancer Res; 2015 Dec; 75(23):5093-105. PubMed ID: 26573794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
    Coutinho I; Day TK; Tilley WD; Selth LA
    Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer.
    Ferrari N; Granata I; Capaia M; Piccirillo M; Guarracino MR; Venè R; Brizzolara A; Petretto A; Inglese E; Morini M; Astigiano S; Amaro AA; Boccardo F; Balbi C; Barboro P
    Cell Commun Signal; 2017 Dec; 15(1):51. PubMed ID: 29216878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reconsideration of progression to CRPC during androgen deprivation therapy.
    Mizokami A; Namiki M
    J Steroid Biochem Mol Biol; 2015 Jan; 145():164-71. PubMed ID: 24717975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy.
    Fiandalo MV; Wu W; Mohler JL
    Curr Drug Targets; 2013 Apr; 14(4):420-40. PubMed ID: 23565755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
    Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.